Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8840924 | NEOS THERAPS | Compositions and methods of making rapidly dissolving ionically masked formulations |
Apr, 2026
(1 year, 11 months from now) | |
US9265737 | NEOS THERAPS | Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles |
Jun, 2032
(8 years from now) | |
US9017731 | NEOS THERAPS | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles |
Jun, 2032
(8 years from now) | |
US8709491 | NEOS THERAPS | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles |
Jun, 2032
(8 years from now) |
Adzenys Xr-Odt is owned by Neos Theraps.
Adzenys Xr-Odt contains Amphetamine.
Adzenys Xr-Odt has a total of 4 drug patents out of which 0 drug patents have expired.
Adzenys Xr-Odt was authorised for market use on 27 January, 2016.
Adzenys Xr-Odt is available in tablet, orally disintegrating, extended release;oral dosage forms.
The generics of Adzenys Xr-Odt are possible to be released after 28 June, 2032.
Drugs and Companies using AMPHETAMINE ingredient
Market Authorisation Date: 27 January, 2016
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL